Gepirone Organon

Current Opinion in Investigational Drugs

Volumn 2, Issue 8, 2001, Pages 1120-1127

  Leslie, R A ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 PYRIMIDINYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; BMY 13805 1; BUSPIRONE; CLOMIPRAMINE; DIAZEPAM; DOPAMINE 2 RECEPTOR; FLESINOXAN; FLUOXETINE; GEPIRONE; IMIPRAMINE; PAROXETINE; PLACEBO; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ANXIETY NEUROSIS; AREA UNDER THE CURVE; CHEMICAL MODIFICATION; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; INSOMNIA; LONG TERM CARE; NAUSEA; NEUROTRANSMISSION; NONHUMAN; RECEPTOR SENSITIVITY; REVIEW; SHORT COURSE THERAPY; STRUCTURE ACTIVITY RELATION; SUSTAINED RELEASE FORMULATION; TOXICITY TESTING; VERTIGO;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; PYRIMIDINES; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034861387     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. 1A) partial agonist in the treatment of major depression
2. A pilot trial of gepirone vs. placebo in the treatment of cocaine dependency
3. Serotonergic involvement in conflict behaviour
4. 1A autoreceptor response and its evaluation as a model to selectively identify antidepressants
5. The site of gastrointestinal absorption of gepirone in humans
6. The comparison of benzodiazepine derivatives and serotoninergic agonist and antagonists in two animal models of anxiety
7. Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm
8. Clinical profile of gepirone, a nonbenzodiazepine anxiolytic
9. 1A agonists buspirone and gepirone
10. Strychnine seizure potentiation by azaspirodecanedione anxiolytics in rats
11. The alpha 2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP)
12. 1A agonists, 8-OH-DPAT and gepirone, to increase hypertonic saline consumption in the rat: Evidence against a general hyperdipsic action
13. 1A receptor-mediated effects of buspirone, gepirone and ipsapirone
14. Reversal of helpless behavior in rats by putative 5-HT-1(a) agonists
15. 1A agonists. A new therapeutic principle for stroke treatment
16. Antidepressant-like activity of ipsapirone, buspirone and gepirone in the forced swimming test in rats pretreated with proadifen
17. 1A receptor agonists
18. Actions of 5-HT-1 ligands on excitatory synaptic transmission in the hippocampus of alert rats
19. Gepirone in the treatment of major depression
20. Differential effect of gepirone on presynaptic and postsynaptic serotonin receptors: Single-cell recording studies
21. 1A agonist gepirone in depressed patients
22. 1A agonist, in the learned helplessness paradigm: Evidence for a postsynaptic mechanism
23. Intramural research program, serotonin receptor and reuptake sites: Pharmacologic significance
24. The effects of gepirone on neuroendocrine function and temperature in humans
25. Anticonflict effect of ipsapirone, buspirone and gepirone is not mediated by their common metabolite 1-(2-pyrimidinyl) piperazine
26. 1A receptors in rat brain following antidepressant drug treatment
27. 5-HT-1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis
28. The effects of gepirone and 1-(2-pyrimidinyl)-piperazine on levels of corticosterone in rat plasma
29. 1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in rat hippocampal membranes
30. Effect of gepirone and ipsapirone on the stimulated and unstimulated secretion of prolactin in the rat
31. Unique modulation of central 5-HT-2 receptor binding sites and 5-HT-2 receptor-mediated behavior by continuous gepirone treatment
32. 1A receptor sensitivity: A neuroendocrine study in healthy volunteers
33. Influence of taste and food texture on the feeding responses induced by 8-OH-DPAT and gepirone
34. Gepirone and the treatment of panic disorder: An open study
35. Gepirone and 1-(2-pyrimidinyl)-piperazine-induced reduction of aversively evoked ultrasonic vocalization in the rat
36. 1A neurons of the dorsal raphe
37. Licensing information
38. 1A agonist gepirone on operant and non-operant food intake in food-deprived rats
39. Gepirone treatment of atypical depression: Preliminary evidence of serotonergic involvement
40. Diazepam withdrawal: Effects of diazepam and gepirone on acoustic startle-induced 22 kHz ultrasonic vocalizations
41. Effect of food on the bioavailability of gepirone in humans
42. 1A receptor agonists: Recent developments and controversial issues
43. Active behaviors in the rat forced swimming test differentially produced by serotonergic and nonadrenergic antidepressants
44. Alcohol, anxiolytics and social stress in rats
45. Fabre-Kramer gepirone NDA for depression under preparation
46. A double-blind trial of low- and high-dose ranges of gepirone - ER compared with placebo in the treatment of depressed outpatients
47. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression
48. Gepirone and diazepam in generalized anxiety disorder: A placebo-controlled trial
49. The forced swimming test as a model for core and component behavioural effects of antidepressant drugs
50. New approaches to rapid onset antidepressants
51. Drug development pipeline: Gepirone
52. Drug development pipeline: Tri-Dosogen, etonogestrel contraceptive implant, vaginal ring (contraceptive), Organon, Org-30659, male hormone program, Organon, rFSH, Organon, ganirelix,Org-12962, gepirone,Org-5222, danaparoid sodium,SR-34006, rimexolone, rapacuronium bromide, Org-32782, Org-36764, VUF-8929, CERM-12816,Org-2766, Org-30850, tibolone, Org-33408
53. Lehman Brothers: A guide to product submissions and approvals in 2000
54. Akzo nobel: Labeled Europe's fastest growing pharmaceutical company
55. Akzo nobel: Solid upward trend continuing
56. Drug development pipeline: Organon
57. The discovery and development of buspirone: A new approach to treatment of anxiety
58. Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: Human cytochromes mediating transformation and cytochrome inhibitory effects
59. Annual report 2000: Akzo Nobel
60. 1A agonist ORG-33062 (gepirone HCI) and its metabolite ORG-25907 (3-OH-gepirone) on the 5-HT system in the rat brain
61. 1A receptor agonist ORG 33062 (gepirone HCI) and its metabolite ORG 25907 (3-OH-gepirone)
62. The Quidnunc - Pharma focus
63. Akzo Nobel